Aimed Bio Inc. (Ticker: 0009K0 KS) is a South Korean biotechnology company specializing in the development of antibody-drug conjugate (ADC) anti-cancer therapeutics. Established as a spin-off from Samsung Medical Center, the company leverages patient-derived cell models and proprietary linker-payload technology to identify therapeutic targets.

Aimed Bio plans to list on the KOSDAQ market on December 4, 2025, offering 6.43 million shares at a fixed price of 11,000 KRW. The transaction aims to raise 70,730 million KRW (approximately US$47.96 million). Based on the total post-IPO share count of roughly 64.1 million, the company holds an implied market capitalization of approximately 705.7 billion KRW (US$479 million). Aimed Bio reportedly plans to use the IPO proceeds to fund further research and development of its drug pipeline. Mirae Asset Securities serves as the lead underwriter.